RhoVac Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

RhoVac şirketinin toplam hissedar öz sermayesi SEK12.8M ve toplam borcu SEK0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla SEK33.0M ve SEK20.2M dir.

Anahtar bilgiler

Borç/özkaynak oranı

SEK 0

Borç

Faiz karşılama oranı	n/a
Nakit	SEK 9.92m
Eşitlik	SEK 12.78m
Toplam yükümlülükler	SEK 20.21m
Toplam varlıklar	SEK 33.00m

Son finansal sağlık güncellemeleri

Recent updates

We're Keeping An Eye On RhoVac's (NGM:RHOVAC) Cash Burn Rate

Feb 12

RhoVac (NGM:RHOVAC) Is In A Good Position To Deliver On Growth Plans

Aug 27

Is RhoVac (NGM:RHOVAC) In A Good Position To Deliver On Growth Plans?

Mar 23

We Think RhoVac (NGM:RHOVAC) Can Easily Afford To Drive Business Growth

Dec 08

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: RHOVAC 'nin kısa vadeli varlıkları ( SEK33.0M ) kısa vadeli yükümlülüklerini ( SEK20.2M ) aşıyor.

Uzun Vadeli Yükümlülükler: RHOVAC un uzun vadeli yükümlülüğü bulunmamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: RHOVAC borçsuzdur.

Borcun Azaltılması: RHOVAC un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: RHOVAC şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: RHOVAC un, serbest nakit akışı her yıl % 21.8 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

RhoVac Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

We're Keeping An Eye On RhoVac's (NGM:RHOVAC) Cash Burn Rate

RhoVac (NGM:RHOVAC) Is In A Good Position To Deliver On Growth Plans

Is RhoVac (NGM:RHOVAC) In A Good Position To Deliver On Growth Plans?

We Think RhoVac (NGM:RHOVAC) Can Easily Afford To Drive Business Growth

Recent updates

Chosa ApS completed the acquisition of RhoVac AB (NGM:RHOVAC) from M2 Asset Management AB (publ) and others in a reverse merger transaction.

RhoVac AB to Report Fiscal Year 2022 Results on Feb 10, 2023

No independent directors

RhoVac AB Announces Resignation of Anders Ljungqvist as Board Member

RhoVac AB to Report Q3, 2022 Results on Nov 11, 2022

RhoVac AB Appoints Lars Hedbys as Acting CEO, Starting from September 1, 2022

RhoVac AB to Report Q2, 2022 Results on Aug 26, 2022

Rhovac AB Announces Resignation of Anders Månsson as CEO

RhoVac AB's Phase IIb Study in Prostate Cancer , BRaVac, Failed to Meet Its Primary Endpoint

Pre-Clinical Findings Support the Potential Use of RhoVac AB's Drug Candidate, Onilcamotide, Across Several Cancers

No independent directors

RhoVac AB Announces Scientific Publication Supports its Cancer Treatment Method

We're Keeping An Eye On RhoVac's (NGM:RHOVAC) Cash Burn Rate

RhoVac AB Announces Another Clean Interim Safety Review of Clinical Phase IIb Study in Prostate Cancer

RhoVac's Market Research Shows Great Potential for A Cancer Vaccine Preventing Recurrence of Metastatic Disease in Multiple Cancers

Rhovac Announces the Completion of Patient Recruitment for the Bravac Clinical Phase Iib Study of Rv001 in Prostate Cancer

RhoVac (NGM:RHOVAC) Is In A Good Position To Deliver On Growth Plans

RhoVac AB Receives Approval to Initiate a Long-Term Follow-Up of Clinical Phase I/II Patients

Is RhoVac (NGM:RHOVAC) In A Good Position To Deliver On Growth Plans?

Rhovac AB Announces the Initiation of First New US Clinic in Company's Phase IIb Study

New 90-day low: kr21.00

Global Covid-19 Vaccination Roll-Out Causes Delay to Rhovac's Phase IIb Study

RhoVac AB Announces First patient in treatment in RhoVac's clinical phase IIb study in United Kingdom

We Think RhoVac (NGM:RHOVAC) Can Easily Afford To Drive Business Growth

New 90-day high: kr21.15

RhoVac's Prostate Cancer Drug Candidate, RV001, is granted Fast Track Designation by the FDA

Rhovac AB Announces That Positive Results from Rhovac's Clinical Phase I/Ii Study Published in Journal of Immunotherapy of Cancer

New 90-day low: kr16.44

RhoVac AB Announces Covid-19 pandemic affecting RhoVac's clinical phase IIb study

New 90-day high: kr20.65

RhoVac AB Announces First Patient in Treatment in Rhovac's Clinical Phase IIb Study in Sweden

RhoVac AB to Report Q2, 2020 Results on Aug 28, 2020

New 90-day high - kr16.98

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin